Monitoring Bleeding of Patients Using NOAC Anticoagulation Therapy in Proximal Femoral Fracture Internal Fixation Surgery Without Waiting. We Measure Bleeding in Surgery and the Levels of Noac Drug in Blood. We Will Try to Compare to Regular Pateints Later
Bleeding of Patients Using NOAC Anticoagulation Therapy in Proximal Femoral Fracture Internal Fixation Surgery
1 other identifier
observational
100
1 country
1
Brief Summary
until today we waited at least 24 hours before surgery of femoral neck fractures in patients who take anticouagolation . in our new reasearch we belive that patients who take NOAC can go under surgery earlier with minimal risk
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Aug 2024
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 20, 2024
CompletedFirst Submitted
Initial submission to the registry
October 14, 2024
CompletedFirst Posted
Study publicly available on registry
October 16, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2025
CompletedOctober 16, 2024
October 1, 2024
1.3 years
October 14, 2024
October 14, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
bleeding
30 days
Study Arms (2)
early surgery
late surgery
Interventions
femoral neck fracture CRiF while under noac. no special intervention beside taking blood test for drug levels
Eligibility Criteria
patients with femoral neck fracture thattake noac and arrive at meir hospital and need surgery
You may qualify if:
- above 18 y.o femoral neck fracture NOAC capable of making inform consent primary surgery
You may not qualify if:
- under 18 y.o
- anti platelet therapy (aspirin is not included)
- creatinine clearance under 50
- active anti cancer therapy
- ITP patients
- non capable of making inform consent
- patients which decide not to proceed with the expeirment
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Meir Hospital
Kfar Saba, 4428164, Israel
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Dr. meron pinchas talmor
Study Record Dates
First Submitted
October 14, 2024
First Posted
October 16, 2024
Study Start
August 20, 2024
Primary Completion
December 1, 2025
Study Completion
December 1, 2025
Last Updated
October 16, 2024
Record last verified: 2024-10
Data Sharing
- IPD Sharing
- Will not share